|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Jaguar Health, Inc.
| | | Phone: | (415) 371-8300 | Year Established: | 2013 | Ticker: | JAGX | Exchange: | NASDAQ | Main Contact: | Lisa Conte, Founder & CEO | | Other Contacts: | Karen Wright, CFO Victoria Lewis, Chief of Clinical Development Rustom Masalawala, Senior VP, International Markets Bobba Venkatadri, Ecexutive VP, Manufacturing and Supply Chain Ian Parker, Senior VP, Commercial Operations Philippe Brianceau, DVM, Chief Veterinary Officer John Kallassy, CFO & COO Steven KKaren Wrighting, Ph.D., Executive VP of Sustainable Supply & IP
| | Company Description | Jaguar Health is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia™ is Jaguar’s lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm™ Calf is the company’s lead non-prescription product. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm is a standardized botanical extract derived from the Croton lechleri tree. Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has filed nine Investigational New Animal Drug applications, or INADs, with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species, and formulations of Canalevia for cats, horses and dogs. | |
|
|
|
|
|